Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Thrombosis and Haemostasis

• Publication date

  2010-11-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH10-03-0194PMID 21057703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy

  2010cited by this paper
• Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?

  2010cited by this paper
• Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements

  2010cited by this paper
• Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study

  2010cited by this paper
• Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

  2009influential reference
• Pharmacogenetic Testing for Guiding de novo Phenprocoumon Therapy in Stroke Patients

  2009cited by this paper
• Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram

  2009cited by this paper
• Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements

  2009cited by this paper
• The largest prospective warfarin-treated cohort supports genetic forecasting.

  2009cited by this paper
• Subtherapeutic oral anticoagulant therapy: Frequency and risk factors

  2009cited by this paper
• Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation

  2009cited by this paper
• Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes

  2009cited by this paper
• Pharmacogenetics of Oral Anticoagulants

  2008cited by this paper
• Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon

  2008cited by this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008influential reference
• An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients

  2008cited by this paper
• Combination of Phenotype Assessments and CYP2C9‐VKORC1 Polymorphisms in the Determination of Warfarin Dose Requirements in Heavily Medicated Patients

  2008cited by this paper
• VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

  2007cited by this paper
• The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol

  2007cited by this paper
• Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

  2007cited by this paper
• Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles

  2007cited by this paper
• VKORC1: molecular target of coumarins

  2007cited by this paper
• Vitamin K: The coagulation vitamin that became omnipotent

  2007cited by this paper
• Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin

  2006cited by this paper
• The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

  2006cited by this paper
• Common VKORC1 and GGCX polymorphisms associated with warfarin dose

  2005cited by this paper
• A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

  2005cited by this paper
• A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk

  2005cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

  2005cited by this paper
• Common Genetic Variants of Microsomal Epoxide Hydrolase Affect Warfarin Dose Requirements Beyond the Effect of Cytochrome P450 2C9

  2005cited by this paper
• The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats.

  2004cited by this paper
• Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

  2004cited by this paper
• Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

  2004cited by this paper
• Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

  2004cited by this paper
• The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

  2004cited by this paper
• Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin.

  2004cited by this paper
• Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity.

  2003cited by this paper
• Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon

  2003cited by this paper
• Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance

  2002cited by this paper
• Genetic Modulation of Oral Anticoagulation with Warfarin

  2000cited by this paper
• Epoxide hydrolase--polymorphism and role in toxicology.

  2000cited by this paper
• Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration.

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Warfarin Resistance Is Associated with a Protein Component of the Vitamin K 2,3-Epoxide Reductase Enzyme Complex in Rat Liver

  1998cited by this paper
• Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle.

  1998cited by this paper
• Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression.

  1997cited by this paper
• Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants.

  1994cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

  1993cited by this paper

• Frequencies of VKORC1-1639G>A and rs397509427 in Patients on Warfarin and Healthy Syrian Subjects

  2023cites this paper
• Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms

  2020cites this paper
• Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement.

  2019cites this paper
• Genotype phenotype correlation in a pediatric population with antithrombin deficiency

  2019cites this paper
• Human Antithrombin III Minigene with an Optimized Splicing Pattern

  2019cites this paper
• A series of 10 Polish patients with thromboembolic events and antithrombin deficiency: two new c.1154-1 G>C and c.1219-534 A>G SERPINC1 gene splicing mutations.

  2019cites this paper
• A human antithrombin isoform dampens inflammatory responses and protects from organ damage during bacterial infection

  2019cites this paper
• A novel variation of SERPINC1 caused deep venous thrombosis in a Chinese family

  2019cites this paper
• Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

  2018cites this paper
• Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin- Alpha can Influence Warfarin Treatment

  2015cites this paper
• Warfarin Dosage Response Related Pharmacogenetics in Chinese Population

  2015influential citation
• Effect of gene polymorphims on the warfarin treatment at initial stage

  2015cites this paper
• Pharmacogenetics of coumarin anticoagulant therapy

  2015cites this paper
• Respiratory Viral Infections and Subversion of Cellular Antioxidant Defenses

  2014cites this paper
• A New Algorithm for Weekly Phenprocoumon Dose Variation in a Southern Brazilian Population: Role for CYP2C9, CYP3A4/5 and VKORC1 Genes Polymorphisms

  2014cites this paper
• Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9‐mediated dose requirements of vitamin K antagonist therapy: a pilot study

  2014cites this paper
• A Pharmacogenetics-Based Warfarin Maintenance Dosing Algorithm from Northern Chinese Patients

  2014cites this paper
• Cohort study on the quality of oral anticoagulation therapy in chronic haemodialysis patients treated with phenprocoumon.

  2013cites this paper
• Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.

  2013cites this paper
• Towards optimal dosing of coumarin derivatives: the role of pharmacogenetics

  2013cites this paper
• Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon.

  2013cites this paper
• Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms

  2013cites this paper
• Cryptic chromosome rearrangements in five patients, with normal and/or abnormal karyotypes, associated with mental retardation, autism and/or epilepsy, detected by BAC genome array-CGH.

  2012cites this paper
• Pharmacogenetics in clinical practice.

  2012cites this paper
• Rational and safe dosing of phenprocoumon during loading and maintenance phase

  2012cites this paper
• A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in Han Chinese patients with non valvular atrial fibrillation

  2012cites this paper
• Validation of a Rapid and Inexpensive Allele-Specific Amplification (ASA)-PCR Genotyping Assay for Vitamin K Antagonist Pharmacogenomics

  2011cites this paper
• Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multiethnic Asian population

  2011cites this paper
• Validation of a rapid and inexpensive allele-specific amplification (ASA)-PCR genotyping assay for vitamin K antagonist pharmacogenomics.

  2011cites this paper
• Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters

  2010cites this paper